2023 - Research.com Medicine in Italy Leader Award
His primary areas of study are Breast cancer, Internal medicine, Oncology, Pathology and Cancer. His Breast cancer study combines topics in areas such as Clinical trial and Surgery. His research in Surgery intersects with topics in Sentinel lymph node, Mastectomy, Lymph node and Hazard ratio.
His Internal medicine study combines topics from a wide range of disciplines, such as Endocrinology and Gynecology. His work carried out in the field of Oncology brings together such families of science as Trastuzumab, MammaPrint, Ductal carcinoma, Estrogen receptor and Disease. His Cancer research includes elements of Cancer research and Predictive value of tests.
His primary scientific interests are in Breast cancer, Internal medicine, Oncology, Pathology and Cancer. The concepts of his Breast cancer study are interwoven with issues in Biopsy, Gynecology, Surgery and Disease. His Surgery research is multidisciplinary, incorporating elements of Mastectomy, Metastasis, Sentinel node and Axilla.
His biological study spans a wide range of topics, including Clinical trial, Trastuzumab, Proportional hazards model, Triple-negative breast cancer and Adjuvant therapy. His Pathology research integrates issues from Breast carcinoma and Adenocarcinoma. His Cancer study incorporates themes from Gastroenterology and Cancer research.
Giuseppe Viale mostly deals with Internal medicine, Breast cancer, Oncology, Hazard ratio and Clinical trial. His Breast cancer research is multidisciplinary, relying on both Clinical endpoint and Confidence interval. His Oncology research incorporates elements of MEDLINE, Tamoxifen, Disease, Triple-negative breast cancer and Cohort.
His Hazard ratio research is multidisciplinary, incorporating perspectives in Proportional hazards model, Mastectomy, MammaPrint and Adjuvant therapy. The study incorporates disciplines such as Cancer research and Immune system in addition to Cancer. His Surgery research includes elements of Sentinel node and Axilla.
His primary areas of investigation include Breast cancer, Internal medicine, Oncology, Hazard ratio and Clinical trial. His work deals with themes such as Immunohistochemistry, MEDLINE, Confidence interval, Clinical endpoint and Proportional hazards model, which intersect with Breast cancer. His Oncology research is multidisciplinary, incorporating perspectives in Trastuzumab, Guideline, Tamoxifen, Estrogen receptor and Estrogen.
Giuseppe Viale studied Estrogen receptor and Carcinoma that intersect with Statistical significance, Univariate analysis, Lymph node and Retrospective cohort study. His studies in Hazard ratio integrate themes in fields like Predictive value of tests, Chemotherapy regimen, MammaPrint and Anastrozole. His work carried out in the field of Surgery brings together such families of science as Mastectomy, Sentinel node and Axilla.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Antonio C Wolff;M Elizabeth Hale Hammond;Kimberly H Allison;Brittany E Harvey.
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond;Daniel F Hayes;Mitch Dowsett;D Craig Allred.
Journal of Clinical Oncology (2010)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.
Umberto Veronesi;Giovanni Paganelli;Giuseppe Viale;Alberto Luini.
The New England Journal of Medicine (2003)
Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.
Umberto Veronesi;Giovanni Paganelli;Viviana Galimberti;Giuseppe Viale.
The Lancet (1997)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado;C. Denkert;S. Demaria;N. Sirtaine.
Annals of Oncology (2015)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C. Wolff;M. Elizabeth H Hammond;David G. Hicks;Mitch Dowsett.
Archives of Pathology & Laboratory Medicine (2014)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett;Torsten O. Nielsen;Roger A’Hern;John Bartlett.
Journal of the National Cancer Institute (2011)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fatima Cardoso;Laura J. van’t Veer;Jan Bogaerts;Leen Slaets.
The New England Journal of Medicine (2016)
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
Marc Buyse;Sherene Loi;Laura van't Veer;Giuseppe Viale.
Journal of the National Cancer Institute (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: